EP3917507A4 - Tumeszenzinfiltrationsarzneimittelabgabe von cannabinoiden - Google Patents

Tumeszenzinfiltrationsarzneimittelabgabe von cannabinoiden Download PDF

Info

Publication number
EP3917507A4
EP3917507A4 EP20747957.7A EP20747957A EP3917507A4 EP 3917507 A4 EP3917507 A4 EP 3917507A4 EP 20747957 A EP20747957 A EP 20747957A EP 3917507 A4 EP3917507 A4 EP 3917507A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
administration
tumescent infiltration
tumescent
infiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20747957.7A
Other languages
English (en)
French (fr)
Other versions
EP3917507A1 (de
Inventor
Jeffrey Alan Klein
Paytra Alan Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hk Tumescent Pharma
Original Assignee
HK Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/264,440 external-priority patent/US11241412B2/en
Application filed by HK Pharma filed Critical HK Pharma
Publication of EP3917507A1 publication Critical patent/EP3917507A1/de
Publication of EP3917507A4 publication Critical patent/EP3917507A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20747957.7A 2019-01-31 2020-01-30 Tumeszenzinfiltrationsarzneimittelabgabe von cannabinoiden Pending EP3917507A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/264,440 US11241412B2 (en) 2015-10-12 2019-01-31 Tumescent infiltration drug delivery of cannabinoids
PCT/US2020/015963 WO2020160328A1 (en) 2019-01-31 2020-01-30 Tumescent infiltration drug delivery of cannabinoids

Publications (2)

Publication Number Publication Date
EP3917507A1 EP3917507A1 (de) 2021-12-08
EP3917507A4 true EP3917507A4 (de) 2022-11-09

Family

ID=71840463

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20747957.7A Pending EP3917507A4 (de) 2019-01-31 2020-01-30 Tumeszenzinfiltrationsarzneimittelabgabe von cannabinoiden

Country Status (2)

Country Link
EP (1) EP3917507A4 (de)
WO (1) WO2020160328A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
US11241412B2 (en) 2015-10-12 2022-02-08 Hk Pharma Tumescent infiltration drug delivery of cannabinoids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011066577A1 (en) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Tumescent antibiotic solution
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2018081740A1 (en) * 2016-10-28 2018-05-03 The Regents Of The University Of California Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US10493024B2 (en) * 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116223A1 (en) * 2009-03-02 2013-05-09 Doris Hexsel Medicinal cosmetic lipoatrophy
WO2011066577A1 (en) * 2009-11-30 2011-06-03 Jeffrey Alan Klein Tumescent antibiotic solution
WO2018081740A1 (en) * 2016-10-28 2018-05-03 The Regents Of The University Of California Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREGG J M ET AL: "Cardiovascular effects of cannabinol during oral surgery", ANESTHESIA AND ANALGESIA 1976, vol. 55, no. 2, 1976, pages 203 - 213, XP009539446, ISSN: 0003-2999 *
NEWTON S C ET AL: "In vitro effects of psychoactive and non-psychoactive cannabinoids on immature rat sertoli cell function", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 53, no. 18, 1 January 1993 (1993-01-01), pages 1429 - 1437, XP023740434, ISSN: 0024-3205, [retrieved on 19930101], DOI: 10.1016/0024-3205(93)90585-Q *
See also references of WO2020160328A1 *

Also Published As

Publication number Publication date
WO2020160328A1 (en) 2020-08-06
EP3917507A1 (de) 2021-12-08

Similar Documents

Publication Publication Date Title
IL283234A (en) Cannabidiol-type cannabinoid compound
IL286846A (en) Camptothecin derivatives
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
EP4045024A4 (de) Transdermale verabreichung von cannabidiol
SI3743406T1 (sl) Modulatorji TMEM16A
LT3728238T (lt) Sulfonilkarbamido dariniai kaip nlrp3 uždegimo moduliatoriai
DK3978095T3 (da) Cpc fordelingskromatografi af cannabinoider
EP3538078A4 (de) Formulierungen zur effizienten verabreichung von cannabinoiden
EP4038058A4 (de) Cannabinoidderivate
IL264461A (en) Cannabis composition
IL264975A (en) Instant installation of apps
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
EA201692437A1 (ru) Комбинация
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
EP4073033A4 (de) Cannabinoidderivate
IL264203A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
PE20170440A1 (es) Derivados de isoindolina
BR112017022281A2 (pt) métodos para tratar câncer
EP3891070A4 (de) Skyport für estol
EP3742228A4 (de) Fotopolymerzusammensetzung
IL280047A (en) Formulation of cannabinoid compounds
IL283059A (en) Continuous flow synthesis of cannabidiol
HRP20181570T1 (hr) Režim doziranja spoja fgf-18
DK3846810T3 (da) Kronisk aftendosering af lasmiditan for migræneforebyggelse

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066815

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 23/02 20060101ALI20221004BHEP

Ipc: A61K 31/522 20060101ALI20221004BHEP

Ipc: A61K 31/352 20060101ALI20221004BHEP

Ipc: A61K 31/137 20060101AFI20221004BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HK TUMESCENT PHARMA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240731